 , Agents causing hyperkalemia , Agents Causing Muscle Toxicity , alpha-Galactosidase, antagonists & inhibitors , Antiarrhythmic agents , Antiarrhythmics, Class III , Benzofurans , Bradycardia-Causing Agents , BSEP/ABCB11 Inhibitors , BSEP/ABCB11 Substrates , BSEP/ABCB11 Substrates with a Narrow Therapeutic Index , Calcium Channel Blockers , Cardiac Therapy , Cardiovascular Agents , Cytochrome P-450 CYP1A2 Inhibitors , Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) , Cytochrome P-450 CYP1A2 Inhibitors (strong) , Cytochrome P-450 CYP2A6 Inhibitors , Cytochrome P-450 CYP2A6 Inhibitors (moderate) , Cytochrome P-450 CYP2C19 Inhibitors , Cytochrome P-450 CYP2C19 inhibitors (strength unknown) , Cytochrome P-450 CYP2C19 Inhibitors (weak) , Cytochrome P-450 CYP2C19 Substrates , Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index , Cytochrome P-450 CYP2C8 Substrates , Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index , Cytochrome P-450 CYP2C9 Inhibitors , Cytochrome P-450 CYP2C9 Inhibitors (moderate) , Cytochrome P-450 CYP2D6 Inhibitors , Cytochrome P-450 CYP2D6 Inhibitors (weak) , Cytochrome P-450 CYP3A Inhibitors , Cytochrome P-450 CYP3A Substrates , Cytochrome P-450 CYP3A4 Inhibitors , Cytochrome P-450 CYP3A4 Inhibitors (strength unknown) , Cytochrome P-450 CYP3A4 Inhibitors (strong) , Cytochrome P-450 CYP3A4 Substrates , Cytochrome P-450 CYP3A4 Substrates (strength unknown) , Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Substrates , Drugs causing inadvertant photosensitivity , Enzyme Inhibitors , Heterocyclic Compounds, Fused-Ring , Highest Risk QTc-Prolonging Agents , Hypotensive Agents , Membrane Transport Modulators , Narrow Therapeutic Index Drugs , OCT2 Inhibitors , P-glycoprotein inducers , P-glycoprotein inhibitors , Photosensitizing Agents , Potassium Channel Blockers , QTc Prolonging Agents , Sodium Channel Blockers , Vasodilating Agents